[Skip to Content]
[Skip to Content Landing]
Views 482
Citations 0
Invited Commentary
November 27, 2019

Determining Hypertrophic Cardiomyopathy Mortality: Gaining Wisdom From Knowledge

Author Affiliations
  • 1University Health Network, Peter Munk Cardiac Center, Toronto General Hospital, Toronto, Ontario, Canada
  • 2Department of Medicine, University of Toronto, Toronto, Ontario, Canada
JAMA Cardiol. Published online November 27, 2019. doi:https://doi.org/10.1001/jamacardio.2019.4548

Risk stratification is tremendously important in hypertrophic cardiomyopathy (HCM). It defines future quality of life, insurability, and the angst of dealing with possible premature mortality. In this issue of JAMA Cardiology, Lorenzini et al1 detail mortality in patients with HCM in a study of 4893 patients followed up at 7 large European HCM centers of excellence for a median of 6.2 years. They found significant increased mortality in the HCM cohort throughout the life course compared with a matched general European population. This study is important given its large size, the inclusion of data from multiple experienced HCM centers, and high-quality analysis.

×